We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
Read MoreHide Full Article
Acadia Pharmaceuticals Inc. (ACAD - Free Report) reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. In the year-ago quarter, the company had incurred a loss of 42 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 8% year over year to $115.5 million in the first quarter, driven by Nuplazid demand growth. The top line, however, missed the Zacks Consensus Estimate of $124 million. Nuplazid sales declined 11.7% sequentially in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia were up 3% in after-market trading on Wednesday, despite the weaker-than-expected earnings announcement. The stock has plunged 14.8% in the year so far compared with the industry’s 21.2% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses were $128.9 million for the quarter, significantly up from the year-ago quarter. This was due to an upfront payment of $60 million made to Stoke Therapeutics (STOK - Free Report) under the collaboration agreement.
In January 2022, Acadia entered into a license and collaboration agreement with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system.
Acadia and Stoke will share all costs and profits equally for the SYNGAP1 program worldwide.
Selling, general and administrative (SG&A) expenses were $96.7 million, down 13.4% year over year, owing to reduced advertising and promotional costs as well as lower personnel expenses.
As of Mar 31, 2022, Acadia had cash, cash equivalents and investments worth $446 million compared with $520.7 million as of Dec 31, 2021.
2022 Guidance
Acadia reiterated the financial guidance for 2022 it had provided earlier this year.
The company expects Nuplazid net sales of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $542.4 million.
The company expects R&D expenses of $355-$375 million while SG&A expenses are expected to be $360-$380 million in 2022.
Pipeline Updates
In March 2022, Acadia received the action date from the FDA related to its resubmitted supplemental new drug application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.
The regulatory body has set a target action date of Aug 4, 2022.
Earlier this month, Acadia announced that the FDA’s Advisory Committee meeting to review the resubmission of the sNDA for pimavanserin is scheduled take place on Jun 17, 2022.
The FDA had issued a complete response letter to the sNDA for Nuplazid in April 2021.
Acadia has other promising pipeline candidates that are progressing well.
Last month, the company announced top-line data from a phase II study evaluating the safety and efficacy of its investigational candidate, ACP-044, for the treatment of acute pain following bunionectomy surgery. The study failed to meet its primary endpoint. Shares of Acadia tanked on this news.
Acadia is planning to file a new drug application for trofinetide to treat Rett syndrome around mid-2022.
Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Vertex’s earnings estimates have been revised 0.3% upward for 2022 and 0.2% upward for 2023 over the past 60 days. The VRTX stock has rallied 24.6% year to date.
Earnings of Vertex surpassed estimates in each of the trailing four quarters.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 214.4% year to date.
Earnings of Voyager Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates
Acadia Pharmaceuticals Inc. (ACAD - Free Report) reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. In the year-ago quarter, the company had incurred a loss of 42 cents per share.
Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 8% year over year to $115.5 million in the first quarter, driven by Nuplazid demand growth. The top line, however, missed the Zacks Consensus Estimate of $124 million. Nuplazid sales declined 11.7% sequentially in the reported quarter.
Nuplazid is the first and the only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis.
Shares of Acadia were up 3% in after-market trading on Wednesday, despite the weaker-than-expected earnings announcement. The stock has plunged 14.8% in the year so far compared with the industry’s 21.2% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development (R&D) expenses were $128.9 million for the quarter, significantly up from the year-ago quarter. This was due to an upfront payment of $60 million made to Stoke Therapeutics (STOK - Free Report) under the collaboration agreement.
In January 2022, Acadia entered into a license and collaboration agreement with Stoke Therapeutics to discover, develop and commercialize novel RNA-based medicines for treating neurodevelopmental diseases of the central nervous system.
Acadia and Stoke will share all costs and profits equally for the SYNGAP1 program worldwide.
Selling, general and administrative (SG&A) expenses were $96.7 million, down 13.4% year over year, owing to reduced advertising and promotional costs as well as lower personnel expenses.
As of Mar 31, 2022, Acadia had cash, cash equivalents and investments worth $446 million compared with $520.7 million as of Dec 31, 2021.
2022 Guidance
Acadia reiterated the financial guidance for 2022 it had provided earlier this year.
The company expects Nuplazid net sales of $510-$560 million for 2022. The Zacks Consensus Estimate for the metric is pegged at $542.4 million.
The company expects R&D expenses of $355-$375 million while SG&A expenses are expected to be $360-$380 million in 2022.
Pipeline Updates
In March 2022, Acadia received the action date from the FDA related to its resubmitted supplemental new drug application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.
The regulatory body has set a target action date of Aug 4, 2022.
Earlier this month, Acadia announced that the FDA’s Advisory Committee meeting to review the resubmission of the sNDA for pimavanserin is scheduled take place on Jun 17, 2022.
The FDA had issued a complete response letter to the sNDA for Nuplazid in April 2021.
Acadia has other promising pipeline candidates that are progressing well.
Last month, the company announced top-line data from a phase II study evaluating the safety and efficacy of its investigational candidate, ACP-044, for the treatment of acute pain following bunionectomy surgery. The study failed to meet its primary endpoint. Shares of Acadia tanked on this news.
Acadia is planning to file a new drug application for trofinetide to treat Rett syndrome around mid-2022.
Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise
Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote
Zacks Rank & Stocks to Consider
Acadia currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector are Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and Voyager Therapeutics, Inc. (VYGR - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex’s earnings estimates have been revised 0.3% upward for 2022 and 0.2% upward for 2023 over the past 60 days. The VRTX stock has rallied 24.6% year to date.
Earnings of Vertex surpassed estimates in each of the trailing four quarters.
Voyager Therapeutics’ loss per share estimates have narrowed 38.6% for 2022 and 29% for 2023 over the past 60 days. The VYGR stock has skyrocketed 214.4% year to date.
Earnings of Voyager Therapeutics have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion.